BofA downgraded Candel Therapeutics (CADL) to Neutral from Buy with a $7 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics appoints Carl June to Research Advisory Board
- Candel Therapeutics Extends Lease Agreement in Needham
- Candel Therapeutics Advances with Promising Cancer Therapies
- Candel Therapeutics Faces Uncertainty Despite FDA RMAT Designation for Prostate Cancer Treatment
- Candel Therapeutics’ CAN-2409: Promising Phase 3 Results and Market Potential